XML 35 R29.htm IDEA: XBRL DOCUMENT v3.26.1
Organization - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 14, 2026
Jul. 25, 2025
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Jul. 24, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Exchange ratio in a reverse recapitalization of shares converted   0.3051%                
Accumulated deficit     $ (250,850)       $ (250,850)   $ (230,053)  
Additional paid-in capital     392,964       392,964   $ 363,094  
Net loss     (10,178) $ (10,619) $ (7,585) $ (6,077) (20,797) $ (13,662)    
Cash, cash equivalents and marketable securities     $ 136,200       $ 136,200      
Ikena Oncology, Inc | 2025 PIPE Financing                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Common stock, shares issued   2,508,337                
Reverse Stock Split, at a price   $ 29.9                
Aggregate gross proceeds   $ 75,000                
Voting Common Stock                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Common stock, shares issued     11,279,130       11,279,130   10,650,925  
Common stock, par value     $ 0.001       $ 0.001   $ 0.001  
Common Stock | Ikena Oncology, Inc                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Reverse stock split ratio   8.33%                
Reverse stock split   1-for-12                
Exchange ratio in a reverse recapitalization of shares converted   0.3051%                
Pre-funded Warrants | Voting Common Stock | 2026 Private Placement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Warrants issued and sold to purchase warrant shares 5,770,335                  
Purchase price of warrants $ 5.199                  
Gross proceeds from issuance of warrants $ 30,000                  
Non-OX40 Divestiture                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Additional paid-in capital                 $ 1,500  
Net assets                 5,200  
Cash transferred to buyer for divestiture                 5,200  
Gain (loss) on disposition of business                 $ 0  
Non-OX40 Divestiture | Promissory Note                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Note receivable value   $ 8,900 $ 8,900       $ 8,900      
Assets measure at fair value   $ 6,700                
Ikena CVR Agreement | Contingent Payments Made to Company                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
CVR holder proceeds percentage                   100.00%
Ikena CVR Agreement | Payments Received Under Disposition Agreements                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
CVR holder proceeds percentage                   90.00%
Legacy Inmagene CVR Agreement | Contingent Payments Made to Company                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
CVR holder proceeds percentage                   100.00%
Legacy Inmagene CVR Agreement | Payments Received Under Disposition Agreements                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
CVR holder proceeds percentage                   90.00%
Securities Purchase Agreement | Pre-funded Warrants | Voting Common Stock | 2026 Private Placement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Warrants issued and sold to purchase warrant shares 5,770,335                  
Common stock, par value $ 0.001                  
Purchase price of warrants $ 5.199                  
Gross proceeds from issuance of warrants $ 30,000